CagriSema
Cagri-Sema · cagrilintide/semaglutide · NN9838
Last updated
At a glance
Overview
Why CagriSema Is Worth Paying Attention To#
CagriSema is the first peptide combo that has credibly out-performed semaglutide monotherapy in a head-to-head phase 3 trial — −20.6% bodyweight at 68 weeks vs −14.8% on semaglutide alone vs −3.2% placebo. For physique-focused users who've already run GLP-1s and hit the usual wall (appetite returning, fat loss stalling, lean mass suffering), pairing cagrilintide (a long-acting amylin analog) with semaglutide is the most evidence-backed way to push past that ceiling without jumping to retatrutide.
The mechanism is the reason it works: amylin and GLP-1 hit different satiety circuits. Cagrilintide drives hindbrain-mediated fullness through AMY1/AMY3 receptors; semaglutide hits hypothalamic GLP-1 receptors. You're layering two non-redundant anorexic pathways, not stacking the same lever twice — which is why cagri also blunts the rebound hunger that limits long-run GLP-1 monotherapy.
"Treatment with cagrilintide plus semaglutide resulted in a mean change in body weight of −20.6% at week 68, compared with −14.8% with semaglutide alone and −3.2% with placebo." — Garvey et al., NEJM 2025 (REDEFINE 1)
This guide covers the full protocol: the 16-week titration ladder from 0.25/0.25 mg up to 2.4/2.4 mg weekly, practical reconstitution and co-injection technique, dose selection by goal (aggressive cut vs cruise-phase appetite control vs stall-breaker add-on), stack options including cagri-on-top-of-reta, side-effect management, and how to avoid the single biggest mistake users make on this combo — under-eating protein and bleeding muscle on the way down.
How CagriSema works
Dual-Pathway Satiety: Amylin + GLP-1 Convergence#
CagriSema's core mechanism is the convergence of two anatomically distinct satiety circuits onto the same weekly dosing schedule. Semaglutide agonizes GLP-1 receptors on hypothalamic POMC/AgRP neurons and brainstem GLP-1R populations, suppressing hunger and slowing gastric emptying. Cagrilintide agonizes amylin receptors (AMY1 and AMY3) — calcitonin receptor/RAMP1/RAMP3 heterodimers — concentrated in the area postrema and hypothalamus, producing a separate layer of hindbrain-mediated satiety. Because the two peptides hit non-redundant receptor systems, their anorexic effects stack rather than compete, which is why REDEFINE 1 showed roughly 6 percentage points more weight loss than semaglutide monotherapy at matched doses.
"These data establish AMY1 and AMY3 as the operative brain amylin receptors targeted by cagrilintide to elicit satiety and bodyweight loss." — Gydesen S, et al. EBioMedicine, 2025
Practical consequence: appetite suppression is substantially stronger than either drug alone, and users who titrate too fast get crushed by it. Protein targets become the rate-limiter on muscle retention well before willpower does.
Blunting the GLP-1 Rebound#
A known failure mode of GLP-1 monotherapy is hunger rebound — as exposure plateaus, homeostatic drives to eat reassert themselves and weight loss stalls around month 9–12. Amylin signalling attacks this from a different angle: it slows gastric emptying independently of GLP-1R, suppresses postprandial glucagon, and maintains satiety through the hindbrain rather than the hypothalamus. Adding cagrilintide effectively gives the brain a second satiety input that isn't subject to the same adaptation curve, which is why the combination continues producing weight loss out to 68 weeks in trial data.
"Treatment with cagrilintide plus semaglutide resulted in a mean change in body weight of −20.6% at week 68, compared with −14.8% with semaglutide alone and −3.2% with placebo." — Garvey WT, et al. New England Journal of Medicine, 2025
For physique-focused users, this translates into a longer usable runway before plateau — useful for extended recomps or pre-contest leadups where semaglutide-alone would stall.
Glucose Homeostasis and Insulin Sensitivity#
The glycemic mechanism is also dual-pathway. Semaglutide drives glucose-dependent insulin secretion from pancreatic β-cells and suppresses inappropriate glucagon release, while cagrilintide's amylin activity further suppresses postprandial glucagon and slows nutrient delivery to the small intestine — flattening postprandial glucose excursions. The combined effect on HbA1c is substantial: in REDEFINE 2, nearly three-quarters of T2D participants reached HbA1c ≤6.5% on the combo.
"At week 68, 73.5% of participants in the cagrilintide–semaglutide group had an HbA1c level of 6.5% or lower, compared with 15.9% in the placebo group." — Davies MJ, et al. New England Journal of Medicine, 2025
This is the mechanism physique-focused users care about when they've developed AAS/GH-driven insulin resistance — the combo restores insulin sensitivity without requiring a cycle break, and does it via β-cell-sparing pathways rather than forcing more insulin output.
Gastric Emptying and Nutrient Timing#
Both peptides slow gastric emptying, but through different upstream signals — GLP-1R activation on vagal afferents for semaglutide, amylin receptor activation in the area postrema for cagrilintide. The result is a pronounced delay in gastric transit that extends postprandial fullness for hours. This is simultaneously the mechanism that drives weight loss (lower total intake per eating occasion) and the mechanism behind the GI side-effect profile — nausea, early satiety, and occasional vomiting are not off-target toxicity, they are the therapeutic mechanism at too-high a dose too soon. Slow titration exists specifically to let gastric-emptying tolerance develop alongside the satiety signal.
Pharmacokinetic Matching#
Both peptides are engineered with C18 fatty diacid side chains that bind albumin, extending half-life to ~7 days each. This is not a trivial detail — it's the entire reason the fixed-ratio once-weekly combo is viable. Cagrilintide t½ ≈ 159–195 h; semaglutide t½ ≈ 145–165 h; steady state on both by ~5 weeks of weekly dosing. Phase 1b data confirmed no meaningful PK interaction when co-dosed.
"Cagrilintide and semaglutide coadministration was well tolerated, with a pharmacokinetic profile supporting once-weekly co-dosing and no meaningful pharmacokinetic interactions." — Enebo LB, et al. Lancet, 2021
For the user, this means one injection day per week, stable plasma levels without peak-trough hunger swings, and a clean ~2-month washout when discontinuing — relevant for anyone planning conception or a bulking phase where appetite needs to come back online.
Protocol
CagriSema contains 2 peptides.
| Peptide | Dose / administration | Frequency | Half-Life | Vial |
|---|---|---|---|---|
Cagrilintide Cagrilintide is a long-acting, acylated amylin analogue that agonizes brain amylin receptors (AMY1 and AMY3), leading to slowed gastric emptying, suppression of postprandial glucag... | 0.25–2.4 mg | Weekly | 8 days | 5 mg |
Semaglutide Semaglutide is a once-weekly GLP-1 receptor agonist that targets hypothalamic and brainstem GLP-1R populations, reducing appetite, slowing gastric emptying, and enhancing glucose-d... | 0.25–2.4 mg | Weekly | 7 days | 5 mg |
Reconstituting a blend vial? Use the peptide calculator → — add one entry per peptide above with its vial mg and dose.
Cycle length & outcomes
Documented cycle
16–68 weeks
Plateau after
68 wks
Cycle Structure & Timing#
CagriSema is not a "cycle" compound in the AAS sense — it's a titrate-up, hold, taper-down protocol. The half-life of both peptides (~7 days) means steady state takes 4–5 weeks at each dose step, and the 4-week hold at each rung is what lets GI side effects settle before the next escalation. Skip the titration and you'll be vomiting on the bathroom floor by week 2.
| Goal | Total Cycle Length | Maintenance Dose (each peptide) |
|---|---|---|
| Aesthetic lean-out (lean baseline) | 16–24 weeks | 1.0–1.7 mg weekly |
| Aggressive fat loss (higher BF baseline) | 40–68 weeks | 2.4 mg weekly |
| Off-season / cruise appetite control | Indefinite | 0.5–1.0 mg weekly |
| Pre-prep metabolic reset | 12–16 weeks, then taper | 1.7 mg weekly |
| T2D / insulin resistance recomp | 24–68 weeks | 1.7–2.4 mg weekly |
Standard Titration Ladder#
Mirror the REDEFINE trial schedule. Both peptides move together in a 1:1 ratio; escalate every 4 weeks only if the prior step is well-tolerated.
| Weeks | Cagrilintide | Semaglutide |
|---|---|---|
| 1–4 | 0.25 mg | 0.25 mg |
| 5–8 | 0.5 mg | 0.5 mg |
| 9–12 | 1.0 mg | 1.0 mg |
| 13–16 | 1.7 mg | 1.7 mg |
| 17+ | 2.4 mg | 2.4 mg |
Hold at whichever step gives appetite control without food aversion — plenty of physique-focused users park at 1.0/1.0 or 1.7/1.7 indefinitely because 2.4/2.4 crushes protein intake to the point where holding muscle becomes the limiting factor.
"Treatment with cagrilintide plus semaglutide resulted in a mean change in body weight of −20.6% at week 68, compared with −14.8% with semaglutide alone and −3.2% with placebo." — Garvey et al., NEJM 2025
Onset & Weekly Dose Timing#
- Appetite suppression: noticeable within 48–72 hours of first injection; maximal 5–7 days in.
- Scale weight: typically 0.5–1 lb/week once titrated past 1.0 mg. Dramatic early drops are mostly water and gut content.
- Plateau breaks: expect one with each titration step — the 0.5 → 1.0 and 1.0 → 1.7 jumps usually restart loss after a 2–3 week stall.
- Injection day: pick a consistent day (most users do Sunday night). Side effects peak 24–48 h post-injection, so injecting before a rest day is smarter than before a heavy training day.
- Co-injection: two separate 30G insulin syringes, same SC site session (abdomen or thigh), rotate sites weekly. The phase 1b work confirmed no PK interaction between the two (Enebo et al., Lancet 2021).
On-Cycle Bloodwork#
Baseline labs, then repeat at week 12 and every 12–16 weeks thereafter:
- Lipase (pancreatitis screen)
- HbA1c + fasting glucose
- Full lipid panel
- AST/ALT
- TSH
- CBC + CMP
Any severe persistent abdominal pain → stop injections and pull lipase/imaging immediately. Don't wait and see.
Tapering Off#
Unlike AAS, there's no HPTA recovery issue — but rebound hunger is real and can undo months of work in weeks if you stop cold at top dose. Standard taper:
| Weeks After Discontinuation Decision | Dose |
|---|---|
| 1–2 | 1.7 mg |
| 3–4 | 1.0 mg |
| 5–6 | 0.5 mg |
| 7+ | Off |
During the taper, deliberately dial food intake up to maintenance before hunger returns — this is the single biggest difference between users who keep the loss and users who bounce back 40%+ of their weight within a year.
What to Stack With#
- Testosterone (TRT or cruise dose): the highest-leverage addition for anyone worried about lean mass retention during aggressive fat loss. Physiologic T plus heavy resistance training keeps FFM losses minimal.
- Resistance training + ≥1.6 g/kg protein: non-negotiable, not optional.
- Retatrutide or tirzepatide swap-in: some users replace semaglutide with reta or tirz ("RetaCagri"/"CagriTirz") to push harder on fat loss. Keep the cagrilintide side of the stack for the amylin pathway the GLP-1/GIP agonists don't touch.
- 5-Amino-1MQ or MOTS-c: layer for metabolic/recomp support without adding GI burden.
- Creatine + electrolytes: dehydration from GI symptoms is the most common reason people quit mid-titration. Don't let it.
"Cagrilintide and semaglutide coadministration was well tolerated, with a pharmacokinetic profile supporting once-weekly co-dosing and no meaningful pharmacokinetic interactions." — Enebo et al., Lancet 2021
Run it patient, titrate slow, eat your protein, and the 68-week data is genuinely achievable at home.
Body Transformation Preview
Lean Mass Gain
0.0 lbs
0.0–0.0 lbs range
Fat Loss
20.4 lbs
15.3–25.5 lbs range
Fat Loss by Week
Risks & mistakes
Common (most users)#
- Nausea — the signature GLP-1/amylin side effect, hits hardest in the first 1–2 weeks of each dose step. Mitigate by eating smaller meals, cutting fat and fiber for 48h post-injection, and holding the current step an extra 2–4 weeks before escalating if it's not resolving.
- Early satiety / "food noise gone" — expected and desired, but be deliberate about hitting protein (≥1.6 g/kg target bodyweight). Front-load protein in the first meal of the day before appetite suppression peaks.
- Constipation — very common, driven by slowed gastric emptying plus reduced food volume. 30–40g fiber daily, 3+ L water, magnesium citrate 400mg at night. Add psyllium or kiwifruit if persistent.
- Diarrhea — alternates with constipation for some users. Usually resolves within 1–2 weeks of a new dose step.
- Fatigue / low energy in week 1–2 of each titration step — partly nausea, partly steep caloric deficit. Electrolytes (sodium 3–5g, potassium 1g, magnesium 400mg daily) handle most of it.
- Injection site reactions — mild redness or itch, rotate sites across abdomen, thigh, and upper arm.
- Burping / sulfur burps — classic GLP-1 complaint. Smaller, lower-fat meals fix it.
- Reduced alcohol tolerance — GLP-1 agonism blunts alcohol reward and raises nausea sensitivity. Not a bug.
"Cagrilintide and semaglutide coadministration was well tolerated, with a pharmacokinetic profile supporting once-weekly co-dosing and no meaningful pharmacokinetic interactions." — Enebo et al., Lancet (2021)
Uncommon (dose-dependent or individual)#
- Vomiting — typically signals you titrated too fast. Drop back one step, hold 4 weeks, then re-attempt. If it recurs at the same step, that step is your ceiling.
- Muscle loss — the real physique risk. Drops in lean mass track total weight-loss velocity. If you can't hit protein at 2.4/2.4, back down to 1.7/1.7 or 1.0/1.0 — chasing maximum dose while under-eating protein is the most common mistake on this stack.
- Hair shedding — telogen effluvium secondary to rapid weight loss and/or protein underfeeding, not a direct drug effect. Resolves once weight stabilizes; keep protein high.
- Hypoglycemia when stacked with insulin or sulfonylureas — drop basal insulin 20–30% on injection day and re-titrate from there. Check fingerstick glucose before training for the first 2–3 weeks of any stack change.
- Elevated heart rate (typically +3–6 bpm) — class effect. Check resting HR monthly; if trending >100 bpm at rest, pause escalation.
- Lipase elevation without symptoms — show up on routine bloodwork. Re-check in 4 weeks; persistent 3x ULN without abdominal pain warrants a pause and imaging.
- Gallstones — risk scales with rate of weight loss. Slower titration and staying at 1.7/1.7 rather than pushing 2.4/2.4 reduces incidence.
- Menstrual cycle changes in women — rapid weight loss can shift cycles; usually normalizes at weight stability.
Rare but serious#
- Acute pancreatitis — severe, persistent upper-abdominal pain radiating to the back, often with vomiting. Stop immediately, get lipase and imaging. History of pancreatitis is a hard contraindication, not a relative one.
- Acute cholecystitis — RUQ pain, fever, nausea after eating fat. ER-level symptom, not a "see how it goes" symptom.
- Severe dehydration / AKI — from persistent vomiting or diarrhea. Aggressive oral rehydration; IV fluids if you can't keep water down for 24h.
- Medullary thyroid carcinoma — rodent-data signal for GLP-1 agonists, not confirmed in humans, but warrants the boxed warning. Neck lump, hoarseness, dysphagia → workup.
- Diabetic retinopathy progression — documented with rapid glucose normalization in long-standing T2D. Baseline eye exam if you have T2D history before titrating.
- Severe hypersensitivity reactions — rare with either peptide, rarer still with both. Angioedema or anaphylaxis → stop, don't rechallenge.
Hard contraindications#
- Personal or family history of medullary thyroid carcinoma or MEN2 syndrome — do not use.
- History of pancreatitis — do not use.
- Active gallbladder disease — resolve first.
- Pregnancy, or attempting conception within the next 2 months — both peptides have ~7-day half-lives, requiring a full washout. Discontinue ≥2 months before trying to conceive.
- Breastfeeding — no safety data, do not use.
- Type 1 diabetes — not a studied population; amylin analogs interact meaningfully with endogenous insulin regulation.
- Peptide hypersensitivity to either component — do not attempt with the other alone either.
- Stacking with exogenous insulin without dose reduction — hypoglycemia risk is real. Drop basal 20–30% on injection day and monitor fingerstick glucose.
Sex-specific notes and cycle considerations#
Dosing and titration are identical for both sexes — no virilization concerns, no HPTA suppression, no PCT required. Women typically see absolute fat loss scale proportionally lower than men (roughly 0.55 lb/wk vs 0.7 lb/wk at maintenance dose) simply because of smaller starting mass.
Pregnancy is the only sex-specific hard line: because both peptides have ~7-day half-lives, meaningful drug exposure persists for 5–6 weeks after the last injection. Stop at least 2 months before attempting conception. For men, no fertility concerns are documented — cagrilintide and semaglutide do not affect the HPTA, testicular function, or semen parameters, so this stack is fully compatible with a test cruise or a TRT protocol.
FAQ — CagriSema
Research & citations
4 studies cited on this page.
Conclusion
CagriSema is hands-down the most potent non-stimulant fat-loss tool available for appetite suppression and long-term bodyweight reduction — but the best results come from slow titration, careful dose management, and supporting your recovery and protein intake.
Key takeaways:
- Titrate weekly: start at 0.25 mg cagrilintide + 0.25 mg semaglutide and escalate every 4 weeks up to 2.4 mg of each
- Subcutaneous co-injection, same session and site rotation, once weekly is the standard protocol
- Maintenance dose: 2.4/2.4 mg for maximal appetite suppression and fat loss; 1.0–1.7 mg holds appetite control with fewer GI effects for recomp
- Stack options: testosterone cruise, retatrutide (instead of semaglutide), MOTS-c, or 5-amino-1MQ for multi-pathway fat loss
- Cycle 16–68 weeks; taper off gradually to avoid rebound hunger
- Main side effect is powerful satiety — plan ahead to maintain adequate protein, hydration, and micronutrients
For anyone chasing aggressive fat loss, managing off-season creep, or outgrowing semaglutide alone, CagriSema delivers transformative results — provided you respect the appetite suppression and titrate methodically.
"Treatment with cagrilintide plus semaglutide resulted in a mean change in body weight of −20.6% at week 68, compared with −14.8% with semaglutide alone and −3.2% with placebo."
— Garvey WT et al., NEJM 2025